Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Myriad Genetics Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Myriad Genetics Inc is a small-cap company with a market capitalization of $390M. It ranks number 9 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Gross Margin of 68.8% is the highest of the 9 peers that report one.
A per-ticker accuracy statistic for MYGN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MYGN included.
Follow MYGN free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
| Metric | MYGN | Rank |
|---|---|---|
| Market Cap | $390M | 9/15 |
| P/B Ratio | 1.28x | 8/11 |
| EPS | $-0.84 | – |
| Book Value/Share | $3.18 | – |
| Revenue/Share | $8.43 | – |
| Metric | MYGN | Rank |
|---|---|---|
| ROE | -37.1% | 6/11 |
| ROA | -17.6% | 6/13 |
| ROIC | -19.4% | 7/11 |
| Gross Margin | 68.8% | 1/9 |
| Operating Margin | -12.2% | 5/14 |
| Net Margin | -14.0% | 5/11 |
| EBT Margin | -13.9% | 5/14 |
| Tax Rate | -0.7% | – |
| Metric | MYGN | Rank |
|---|---|---|
| Current Ratio | 2.21x | 9/15 |
| Quick Ratio | 1.98x | 5/9 |
| D/E Ratio | 1.10x | 3/12 |
| Financial Leverage | 2.10x | 3/12 |
| Interest Coverage | -11.8x | 9/14 |
| Working Capital | $158M | 7/15 |
| Metric | MYGN | Rank |
|---|---|---|
| Operating Cash Flow | $8M | 4/16 |
| Metric | MYGN | Rank |
|---|---|---|
| Asset Turnover | 1.26x | 2/12 |
| Receivables Turnover | 7.4x | 7/11 |
| Inventory Turnover | 8.2x | 3/9 |
| Fixed Assets Turnover | 7.4x | 2/12 |
| Days Sales Outstanding | 50 days | 5/11 |
| Days Inventory | 44 days | 7/9 |
| Payables Period | 44 days | 6/9 |
| Cash Conversion Cycle | 50 days | 7/8 |
| Metric | MYGN | Rank |
|---|---|---|
| Total Revenue | $806M | 5/12 |
| Operating Income | -$98M | 12/15 |
| Net Income | -$112M | 9/13 |
| R&D Expense | $106M | 6/16 |
| SG&A Expense | $597M | 4/12 |
| Cost of Goods Sold | $251M | 5/10 |
| Metric | MYGN | Rank |
|---|---|---|
| Shares Outstanding | 96M | – |
| Total Current Assets | $289M | 45.2% of assets |
| Cash & Short-term Investments | $115M | 18.0% of assets |
| Accounts Receivable | $110M | 17.1% of assets |
| Inventory | $31M | 4.8% of assets |
| Total Liabilities | $335M | 52.4% of assets |
| Short-term Debt | $100M | 15.7% of assets |
Companies classified under the same SEC industry code as Myriad Genetics Inc (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Myriad Genetics, Inc. and SOPHiA GENETICS announced a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with ...
Greetings, and welcome to the Myriad Genetics Second Quarter 2022 Financial Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded today, Thursday, August ...
Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.
Our AI ranks Myriad Genetics Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for MYGN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Myriad Genetics Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
17 issuers in our coverage, MYGN included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.